Summary:
- Syndeio, a new biotech company, has been launched to develop innovative neurotherapeutics that target synapses in the brain.
- Synapses are the connections between neurons that allow communication in the brain, and Syndeio's goal is to create therapies that can precisely target and modulate these synaptic connections.
- This approach could lead to new treatments for neurological and psychiatric disorders, as well as potentially enhancing cognitive function and brain health.